Display options
Cite
Singh N, Winston DJ, Razonable RR, et al. Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. J Infect Dis. 2021;223(6):1073-1077doi: 10.1093/infdis/jiaa470.
Singh, N., Winston, D. J., Razonable, R. R., Lyon, G. M., Silveira, F. P., Wagener, M. M., & Limaye, A. P. (2021). Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. The Journal of infectious diseases, 223(6), 1073-1077. https://doi.org/10.1093/infdis/jiaa470
Singh, Nina, et al. "Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy." The Journal of infectious diseases vol. 223,6 (2021): 1073-1077. doi: https://doi.org/10.1093/infdis/jiaa470
Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Limaye AP. Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. J Infect Dis. 2021 Mar 29;223(6):1073-1077. doi: 10.1093/infdis/jiaa470. PMID: 32726431; PMCID: PMC8006424.
Copy Download .nbib Format: NLM
Share it on

J Infect Dis. 2021 Mar 29;223(6):1073-1077. doi: 10.1093/infdis/jiaa470.

Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy.

The Journal of infectious diseases

Nina Singh, Drew J Winston, Raymund R Razonable, G Marshall Lyon, Fernanda P Silveira, Marilyn M Wagener, Ajit P Limaye

Affiliations

  1. University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
  2. University of California Los Angeles Medical Center, Los Angeles, California, USA.
  3. Mayo Clinic, Rochester, Minnesota, USA.
  4. Emory University, Atlanta, Georgia, USA.
  5. University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  6. University of Washington, Seattle, Washington, USA.

PMID: 32726431 PMCID: PMC8006424 DOI: 10.1093/infdis/jiaa470

Abstract

BACKGROUND: The risk factors for development of viremia in high-risk donor cytomegalovirus (CMV)-seropositive and recipient CMV-seronegative (D+R-) transplant recipients are incompletely defined.

METHODS: The study population comprised patients in the preemptive therapy (PET) arm of a randomized, controlled trial of PET versus prophylaxis using valganciclovir in D+R- liver transplant recipients. Weekly surveillance monitoring for viremia for 100 days was performed using a sensitive CMV-DNA polymerase chain reaction assays. Risk factors for viremia and time to onset (≤4 vs >4 weeks) of viremia were examined using logistic regression models.

RESULTS: Viremia developed in 84% (79/94) of recipients and older donor age was the only independent factor associated with viremia (odds ratio, 2.20 for each quartile increase in donor age; 95% confidence interval [CI], 1.07-4.52; P = .031). Recipients who developed early-onset viremia (within 4 weeks) also had significantly older donors than those with later-onset viremia (difference in age 10.1 years; 95% CI, 2-19; P = .03).

CONCLUSIONS: Older donor age was an independent predictor of viremia and earlier-onset of viremia in D+R- liver transplant recipients. Future studies should assess the mechanistic links underlying this novel association.

CLINICAL TRIAL REGISTRATION: NCT01552369.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Keywords: cytomegalovirus; primary CMV infection; transplant; viremia

References

  1. JAMA. 2008 Jul 23;300(4):413-22 - PubMed
  2. Virology (Auckl). 2019 Apr 02;10:1178122X19840371 - PubMed
  3. Am J Transplant. 2012 Sep;12(9):2457-64 - PubMed
  4. J Infect Dis. 2019 Jul 31;220(5):752-760 - PubMed
  5. Immunity. 2013 Jan 24;38(1):187-97 - PubMed
  6. Curr Opin Infect Dis. 2017 Dec;30(6):579-588 - PubMed
  7. Transpl Infect Dis. 2014 Jun;16(3):501-4 - PubMed
  8. J Exp Med. 2017 Mar 6;214(3):651-667 - PubMed
  9. N Engl J Med. 1986 May 29;314(22):1418-23 - PubMed
  10. Clin Transplant. 2019 Sep;33(9):e13512 - PubMed
  11. Exp Gerontol. 2007 Jun;42(6):563-70 - PubMed
  12. Transpl Infect Dis. 2013 Apr;15(2):171-80 - PubMed
  13. JAMA. 2020 Apr 14;323(14):1378-1387 - PubMed
  14. Transplantation. 2004 Dec 27;78(12):1765-73 - PubMed
  15. Anaesth Intensive Care. 2016 Sep;44(5):571-80 - PubMed
  16. Microbiol Spectr. 2016 Aug;4(4): - PubMed
  17. J Virol. 2014 Sep;88(18):10894-908 - PubMed
  18. J Virol. 2014 Dec;88(24):13947-55 - PubMed
  19. Transpl Immunol. 2010 Aug;23(4):166-9 - PubMed

Publication Types

Grant support